Compare Amgen, Inc. (AMGN) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Mercadolibre Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Mercadolibre Inc trades at $1,854 (market cap $93.90B). The key difference: Amgen, Inc. is far larger — about 2.1× Mercadolibre Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| AMGN | MELI | |
|---|---|---|
Market Cap | $196.12B | $93.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $2.51K |
52-Week Low | $271.18 | $1.55K |
Enterprise Value | $241.41B | $100.79B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MercadoLibre (MELI) trades at $1,852.22, up 2.46% today, with a bullish technical signal from moving averages and strong analyst support (23 buy, 0 sell). Revenue grew to $28.89B in 2025, though net income margin compressed to 6.04% amid heavy investment. Recent news highlights investigations by law firms and debates over profitability versus growth, while cash flow from operations surged to $12.12B.
Outlook remains positive given dominant Latin American e-commerce position and 49% revenue growth, but risks include margin pressure from capex, legal scrutiny, and high valuation multiples. The consensus price target of $2,230 implies ~20% upside, contingent on execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
